JPH01301166A - Standard liquid for calibrating blood cell counter - Google Patents
Standard liquid for calibrating blood cell counterInfo
- Publication number
- JPH01301166A JPH01301166A JP13015088A JP13015088A JPH01301166A JP H01301166 A JPH01301166 A JP H01301166A JP 13015088 A JP13015088 A JP 13015088A JP 13015088 A JP13015088 A JP 13015088A JP H01301166 A JPH01301166 A JP H01301166A
- Authority
- JP
- Japan
- Prior art keywords
- particles
- sulfonic acid
- standard solution
- substantially spherical
- average grain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000000601 blood cell Anatomy 0.000 title description 3
- 239000007788 liquid Substances 0.000 title 1
- 239000002245 particle Substances 0.000 claims abstract description 108
- 125000000542 sulfonic acid group Chemical group 0.000 claims abstract description 24
- 239000012086 standard solution Substances 0.000 claims description 34
- 239000008151 electrolyte solution Substances 0.000 claims description 2
- 238000005259 measurement Methods 0.000 abstract description 22
- 210000003743 erythrocyte Anatomy 0.000 abstract description 16
- 239000003792 electrolyte Substances 0.000 abstract description 13
- 238000005534 hematocrit Methods 0.000 abstract description 12
- 210000001772 blood platelet Anatomy 0.000 abstract description 8
- 239000006185 dispersion Substances 0.000 abstract description 7
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 abstract 1
- 239000000178 monomer Substances 0.000 description 16
- 239000012798 spherical particle Substances 0.000 description 12
- 229920002554 vinyl polymer Polymers 0.000 description 12
- 239000000975 dye Substances 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 10
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 9
- 238000006116 polymerization reaction Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- LGWXIBBJZQOXSO-UHFFFAOYSA-L disodium 5-acetamido-4-hydroxy-3-[(2-methylphenyl)diazenyl]naphthalene-2,7-disulfonate Chemical compound [Na+].[Na+].OC1=C2C(NC(=O)C)=CC(S([O-])(=O)=O)=CC2=CC(S([O-])(=O)=O)=C1N=NC1=CC=CC=C1C LGWXIBBJZQOXSO-UHFFFAOYSA-L 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 238000004820 blood count Methods 0.000 description 3
- 239000000982 direct dye Substances 0.000 description 3
- -1 lithium ions Chemical class 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- 239000001488 sodium phosphate Substances 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 2
- IWTYTFSSTWXZFU-UHFFFAOYSA-N 3-chloroprop-1-enylbenzene Chemical compound ClCC=CC1=CC=CC=C1 IWTYTFSSTWXZFU-UHFFFAOYSA-N 0.000 description 2
- WLDHEUZGFKACJH-ZRUFZDNISA-K Amaranth Chemical compound [Na+].[Na+].[Na+].C12=CC=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(O)=C1\N=N\C1=CC=C(S([O-])(=O)=O)C2=CC=CC=C12 WLDHEUZGFKACJH-ZRUFZDNISA-K 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical compound C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 2
- HBBGRARXTFLTSG-UHFFFAOYSA-N Lithium ion Chemical compound [Li+] HBBGRARXTFLTSG-UHFFFAOYSA-N 0.000 description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical class CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920007962 Styrene Methyl Methacrylate Polymers 0.000 description 2
- 238000000862 absorption spectrum Methods 0.000 description 2
- WLDHEUZGFKACJH-UHFFFAOYSA-K amaranth Chemical compound [Na+].[Na+].[Na+].C12=CC=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(O)=C1N=NC1=CC=C(S([O-])(=O)=O)C2=CC=CC=C12 WLDHEUZGFKACJH-UHFFFAOYSA-K 0.000 description 2
- 235000012735 amaranth Nutrition 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- CQEYYJKEWSMYFG-UHFFFAOYSA-N butyl acrylate Chemical compound CCCCOC(=O)C=C CQEYYJKEWSMYFG-UHFFFAOYSA-N 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 238000007334 copolymerization reaction Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- SXQCTESRRZBPHJ-UHFFFAOYSA-M lissamine rhodamine Chemical compound [Na+].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S([O-])(=O)=O)C=C1S([O-])(=O)=O SXQCTESRRZBPHJ-UHFFFAOYSA-M 0.000 description 2
- 229910001416 lithium ion Inorganic materials 0.000 description 2
- ADFPJHOAARPYLP-UHFFFAOYSA-N methyl 2-methylprop-2-enoate;styrene Chemical compound COC(=O)C(C)=C.C=CC1=CC=CC=C1 ADFPJHOAARPYLP-UHFFFAOYSA-N 0.000 description 2
- 239000005011 phenolic resin Substances 0.000 description 2
- 230000000379 polymerizing effect Effects 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 229910001414 potassium ion Inorganic materials 0.000 description 2
- 238000012673 precipitation polymerization Methods 0.000 description 2
- 229910001415 sodium ion Inorganic materials 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 1
- OEPOKWHJYJXUGD-UHFFFAOYSA-N 2-(3-phenylmethoxyphenyl)-1,3-thiazole-4-carbaldehyde Chemical compound O=CC1=CSC(C=2C=C(OCC=3C=CC=CC=3)C=CC=2)=N1 OEPOKWHJYJXUGD-UHFFFAOYSA-N 0.000 description 1
- SBYMUDUGTIKLCR-UHFFFAOYSA-N 2-chloroethenylbenzene Chemical compound ClC=CC1=CC=CC=C1 SBYMUDUGTIKLCR-UHFFFAOYSA-N 0.000 description 1
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
- ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 description 1
- JLBJTVDPSNHSKJ-UHFFFAOYSA-N 4-Methylstyrene Chemical compound CC1=CC=C(C=C)C=C1 JLBJTVDPSNHSKJ-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical group OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- 229910052776 Thorium Inorganic materials 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000000981 basic dye Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- YACLQRRMGMJLJV-UHFFFAOYSA-N chloroprene Chemical compound ClC(=C)C=C YACLQRRMGMJLJV-UHFFFAOYSA-N 0.000 description 1
- XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000000402 conductometric titration Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 150000001993 dienes Chemical class 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- LARMRMCFZNGNNX-UHFFFAOYSA-L disodium 7-anilino-3-[[4-[(2,4-dimethyl-6-sulfonatophenyl)diazenyl]-2-methoxy-5-methylphenyl]diazenyl]-4-hydroxynaphthalene-2-sulfonate Chemical compound [Na+].[Na+].COc1cc(N=Nc2c(C)cc(C)cc2S([O-])(=O)=O)c(C)cc1N=Nc1c(O)c2ccc(Nc3ccccc3)cc2cc1S([O-])(=O)=O LARMRMCFZNGNNX-UHFFFAOYSA-L 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000007720 emulsion polymerization reaction Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- HJWLCRVIBGQPNF-UHFFFAOYSA-N prop-2-enylbenzene Chemical compound C=CCC1=CC=CC=C1 HJWLCRVIBGQPNF-UHFFFAOYSA-N 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 description 1
- 229940077386 sodium benzenesulfonate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- 239000001433 sodium tartrate Substances 0.000 description 1
- 229960002167 sodium tartrate Drugs 0.000 description 1
- 235000011004 sodium tartrates Nutrition 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- MNCGMVDMOKPCSQ-UHFFFAOYSA-M sodium;2-phenylethenesulfonate Chemical compound [Na+].[O-]S(=O)(=O)C=CC1=CC=CC=C1 MNCGMVDMOKPCSQ-UHFFFAOYSA-M 0.000 description 1
- AXMCIYLNKNGNOT-UHFFFAOYSA-M sodium;3-[[4-[(4-dimethylazaniumylidenecyclohexa-2,5-dien-1-ylidene)-[4-[ethyl-[(3-sulfonatophenyl)methyl]amino]phenyl]methyl]-n-ethylanilino]methyl]benzenesulfonate Chemical compound [Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](C)C)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 AXMCIYLNKNGNOT-UHFFFAOYSA-M 0.000 description 1
- MZSDGDXXBZSFTG-UHFFFAOYSA-M sodium;benzenesulfonate Chemical compound [Na+].[O-]S(=O)(=O)C1=CC=CC=C1 MZSDGDXXBZSFTG-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000006277 sulfonation reaction Methods 0.000 description 1
- AKEJUJNQAAGONA-UHFFFAOYSA-N sulfur trioxide Inorganic materials O=S(=O)=O AKEJUJNQAAGONA-UHFFFAOYSA-N 0.000 description 1
- HIFJUMGIHIZEPX-UHFFFAOYSA-N sulfuric acid;sulfur trioxide Chemical compound O=S(=O)=O.OS(O)(=O)=O HIFJUMGIHIZEPX-UHFFFAOYSA-N 0.000 description 1
- 238000010557 suspension polymerization reaction Methods 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 229920001187 thermosetting polymer Polymers 0.000 description 1
- 239000004634 thermosetting polymer Substances 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
Abstract
Description
【発明の詳細な説明】 〔産業上の利用分野〕 本発明は、血球計数器校正用標準液に関する。[Detailed description of the invention] [Industrial application field] The present invention relates to a standard solution for calibrating a hemocytometer.
一般に血液について、その赤血球数や血小板数を計測し
、あるいはヘマトクリッ)1などを計測することは、疾
病の状態などを知るために重要である。このような計測
に際しては、通常、血球計数器が用いられるが、この血
球計数器は高い精度で校正されていることが必要である
。そしてこれをfli8Bするために、従来、ポリマー
粒子の分散液よりなる血球計数器校正用標準液(以下単
に「標準液」という)が用いられている。In general, it is important to measure the number of red blood cells, platelets, or hematocrit (1) of blood in order to know the state of a disease. A blood cell counter is usually used for such measurements, but this blood cell counter needs to be calibrated with high accuracy. In order to fli8B this, conventionally, a standard solution for calibrating a hemocytometer (hereinafter simply referred to as "standard solution") made of a dispersion of polymer particles has been used.
しかしながら、従来の標準液においては、(1)粒子の
分散安定性が低いことから界面活性剤などを標準液に添
加することが必要となり、そのために当該標準液の泡立
ちが激しくて誤計測の原因となるという問題点、並びに
(2)当該標準液における粒子数は、正常な赤血球数に
対応する状態とされており、従って赤血球数の計測につ
いては問題はないが、ヘマトクリット値については、赤
血球と同じ大きさ(6〜9側)の実質上球形の粒子を含
有する標準液を用いると大きく計測されてしまうため、
ヘマトクリット1直については高い信頼性を得ることが
できない、という問題点がある。However, with conventional standard solutions, (1) it is necessary to add surfactants, etc. to the standard solution because the dispersion stability of the particles is low, and this causes the standard solution to foam violently, causing erroneous measurements. (2) The number of particles in the standard solution is said to correspond to the normal number of red blood cells, so there is no problem in measuring the number of red blood cells, but the hematocrit value is different from that of red blood cells. If a standard solution containing substantially spherical particles of the same size (6 to 9 sides) is used, the measurement will be large, so
There is a problem in that high reliability cannot be obtained for one hematocrit shift.
本発明は、上記のような技術的背景においてなされたも
のであって、その目的は、粒子が高い分散安定性を有し
、しかも血小板数や赤血球数の計測およびヘマトクリッ
ト値の計測のいずれについても高い信頼性を存する標準
液を提供することにある。The present invention has been made in the technical background as described above, and its purpose is to provide particles with high dispersion stability and to be suitable for both platelet count, red blood cell count measurement, and hematocrit value measurement. Our goal is to provide highly reliable standard solutions.
以上の本発明の目的は、表面にスルホン酸基および/ま
たはスルホン酸塩基(以下これらを単に「スルホン酸基
」という)を有し平均粒径が1.9〜3卿で変動係数が
5%以下である、実質上球形の第1の粒子と、この第1
の粒子の数の10〜40倍の割合となる数の、表面にス
ルホン酸基を有し平均粒径が4.5〜5.5刺で変動係
数が5%以下である、実質上球形の第2の粒子とが、電
解質水溶液中に分散されていることを特徴とする標準液
によって達成される。The object of the present invention is to have a sulfonic acid group and/or a sulfonic acid group (hereinafter simply referred to as "sulfonic acid group") on the surface, an average particle size of 1.9 to 3 mm, and a coefficient of variation of 5%. a substantially spherical first particle that is
Substantially spherical particles with sulfonic acid groups on the surface, an average particle size of 4.5 to 5.5 spines, and a coefficient of variation of 5% or less, in a proportion of 10 to 40 times the number of particles. This is achieved by a standard solution characterized in that the second particles are dispersed in an aqueous electrolyte solution.
以下、本発明について具体的に説明する。The present invention will be specifically explained below.
本発明の標準液は、各々特定の平均粒径を有する第1の
粒子と第2の粒子とが電解質水溶液に特定の割合で分散
されたものである。The standard solution of the present invention is one in which first particles and second particles each having a specific average particle size are dispersed in an electrolyte aqueous solution at a specific ratio.
第1の粒子は、表面にスルホン酸基を有し、かつ平均粒
径が1.9〜3賜、好ましくは2〜2.92IJ11の
範囲内の実質上球形のものである。この平均粒径の範囲
は、正常なヒトの血小板の大きさと路間等である。The first particles have a sulfonic acid group on the surface and are substantially spherical with an average particle diameter of 1.9 to 3 mm, preferably 2 to 2.92 IJ11. This average particle size range is within the size and tract of normal human platelets.
また、第2の粒子は、表面にスルホン酸基を有し、かつ
平均粒径が4.5〜5,5即の範囲内のものであり、第
1の粒子と同様に実質上球形のものである。この第2の
粒子は赤血球に対応したものであるが、その平均粒径の
範囲は正常なヒトの赤血球の大きさく6〜9μs)より
も小さく、そしてこのことにより、ヘマトクリット値に
ついても高い信頼性を得ることができる。この第2の粒
子の平均粒径が4.5刺未満ではへマトクリフト値が小
さく計測され、また平均粒径が5.5−を越えるとヘマ
トクリット値が大きく計測されるため、いずれの場合も
ヘマトクリット値の計測の標準とすることができなくな
る。Further, the second particles have a sulfonic acid group on the surface, have an average particle size within the range of 4.5 to 5.5 mm, and are substantially spherical like the first particles. It is. This second particle corresponds to red blood cells, but its average particle size range is smaller than the size of normal human red blood cells (6-9 μs), and this makes the hematocrit value highly reliable. can be obtained. If the average particle size of the second particles is less than 4.5 particles, the hematocrit value will be small, and if the average particle size exceeds 5.5, the hematocrit value will be large. It can no longer be used as a standard for measuring values.
本発明において、第1の粒子および第2の粒子(以下こ
れらを「分散粒子」という)について実質上球形とは、
粒子を正投象図法により投影した場合の正面図、立面図
、側面図の各面の像における各最長径をx、ySzとす
るとき、粒子のいずy X x
の値がいずれも0.5から2までの範囲の値となる状態
をいい、好ましくは真球状である。In the present invention, "substantially spherical" for the first particles and the second particles (hereinafter referred to as "dispersed particles") means
When the longest diameters of the front view, elevation view, and side view images of the particles are projected using the orthogonal projection method are x and ySz, the values of y X x of the particles are all 0. It refers to a state in which the value is in the range of .5 to 2, and is preferably perfectly spherical.
上記分散粒子の変動係数、すなわち平均粒径に対する標
準偏差の割合は、いずれも5%以下であることが必要で
あり、更に3%以下であることが好ましい。The coefficient of variation of the dispersed particles, that is, the ratio of the standard deviation to the average particle diameter, must all be 5% or less, and more preferably 3% or less.
本発明における分散粒子は、その各々の表面にスルホン
酸基を有することが必要である。このようなスルホン酸
基を有する分散粒子は、通常、ビニルモノマーから得ら
れる熱可塑性ポリマー、フェノール樹脂などの熱硬化性
ポリマーなどからなり、次のような方法で得ることがで
きる。The dispersed particles in the present invention need to have sulfonic acid groups on their respective surfaces. Such dispersed particles having a sulfonic acid group are usually made of a thermoplastic polymer obtained from a vinyl monomer, a thermosetting polymer such as a phenol resin, and can be obtained by the following method.
(1)式−3O3X (Xはリチウムイオン、カリウム
イオン、ナトリウムイオン、アンモニウムイオンなどの
一価の陽イオンを示す。)で表わされるスルホン酸基を
一有するビニルモノマー、例えばスチレンスルホン酸ナ
トリウム、アクリルアミド−N−プロパンスルホン酸な
どを重合または共重合して分散粒子を得る方法。(1) A vinyl monomer having one sulfonic acid group represented by the formula -3O3X (X represents a monovalent cation such as a lithium ion, potassium ion, sodium ion, or ammonium ion), such as sodium styrene sulfonate, acrylamide - A method for obtaining dispersed particles by polymerizing or copolymerizing N-propanesulfonic acid or the like.
(2) 重合または共重合によりポリマー粒子を合成し
、次いでポリマー粒子の表面にスルホン酸基を導入する
ため、例えばビニルモノマーとして用いたクロルメチル
スチレンに由来する粒子表面のクロルメチル基を重亜硫
酸す) IJウムと反応させる方法、あるいはビニルモ
ノマーとして用いた芳香族ビニルモノマー若しくはフェ
ノール樹脂のモノマーとして用いたフェノールに由来す
る粒子表面のベンゼン環を、濃硫酸、発煙硫酸、無水硫
酸、クロルスルホン酸などと反応させることにより、−
3o、Hを導入し、必要に応じて一3O3Hを、水酸化
リチウム、水酸化カリウム、水酸化ナトリウム、水酸化
アンモニウムなどを用いて、リチウムイオン、カリウム
イオン、ナトリウムイオン、アンモニウムイオンなどの
一価の陽イオンによる塩に変換し、分散粒子を得る方法
。(2) To synthesize polymer particles by polymerization or copolymerization and then introduce sulfonic acid groups onto the surface of the polymer particles, for example, the chloromethyl groups on the particle surface derived from chloromethylstyrene used as a vinyl monomer are replaced with bisulfite) Alternatively, the benzene ring on the particle surface derived from the aromatic vinyl monomer used as the vinyl monomer or the phenol used as the monomer of the phenol resin may be reacted with concentrated sulfuric acid, fuming sulfuric acid, sulfuric anhydride, chlorosulfonic acid, etc. By reacting, −
3O, H is introduced, and if necessary, -3O3H is converted to monovalent ions such as lithium ions, potassium ions, sodium ions, ammonium ions, etc. using lithium hydroxide, potassium hydroxide, sodium hydroxide, ammonium hydroxide, etc. A method of converting into a salt by cations and obtaining dispersed particles.
前記(1〕の方法におけるスルホン酸基を有するビニル
モノマーと共重合し得るモノマーまたは前記(2)の方
法におけるポリマー粒子を合成するためのビニルモノマ
ーとしては、好ましくはスチレン、ビニルトルエン、α
−メチルスチレン、ジビニルベンゼン、クロルメチルス
チレン、クロルスチレンなどの芳香族ビニルモノマーを
挙げることができ、これらのモノマーは1種のみに限ら
れず、2種以上を用いることもできる。また、前記芳香
族ビニルモノマーは、他のビニルモノマーと共重合して
もよく、ここに他のビニルモノマーとしては、ブタジェ
ン、イソプレン、クロロプレンなどの共役ジエン類:メ
チル(メタ)アクリレート、エチル(メタ)アクリレー
ト、ヒドロキシ(メタ)アクリレートなどの(メタ)ア
クリル酸エステル類;塩化ビニノベ塩化ビニリデンなど
のハロゲン化ビニルモノマー類;(メタ)アクリロニト
リル、酢酸ビニル、(メタ)アクリル酸などを挙げるこ
とができる。The monomer copolymerizable with the vinyl monomer having a sulfonic acid group in the method (1) above or the vinyl monomer for synthesizing polymer particles in the method (2) above is preferably styrene, vinyltoluene, α
- Aromatic vinyl monomers such as methylstyrene, divinylbenzene, chloromethylstyrene, and chlorostyrene can be mentioned, and these monomers are not limited to one type, but two or more types can also be used. Further, the aromatic vinyl monomer may be copolymerized with other vinyl monomers, and examples of other vinyl monomers include conjugated dienes such as butadiene, isoprene, and chloroprene; methyl (meth)acrylate, ethyl (meth)acrylate, and ethyl (meth)acrylate; (meth)acrylic acid esters such as acrylate and hydroxy(meth)acrylate; halogenated vinyl monomers such as vinylidene chloride; (meth)acrylonitrile, vinyl acetate, and (meth)acrylic acid.
なお、前記(1)の方法におけるビニルモノマーを重合
または共重合する方法、および前記(2)の方法におけ
る重合または共重合によりポリマー粒子を合成する方法
としては、乳化重合、シード重合、懸濁重合、膨潤重合
、沈澱重合などを挙げることができ、特にシード重合、
沈澱重合または膨潤重合が好ましい。Note that methods for polymerizing or copolymerizing vinyl monomers in method (1) above, and methods for synthesizing polymer particles by polymerization or copolymerization in method (2) above include emulsion polymerization, seed polymerization, and suspension polymerization. , swelling polymerization, precipitation polymerization, etc. In particular, seed polymerization,
Precipitation polymerization or swelling polymerization is preferred.
これらの分散粒子の表面におけるスルホン酸基の密度は
、通常、0.001〜1個/人2、好ましくは0.01
〜0.5個/へ2である。この密度が0.001個/人
2未満では、分散粒子の分散安定性が不十分となって電
解質水溶液中において凝集が生じ易く、一方1個/人2
を超えると、分散粒子の親水性が大きくなりすぎて粒子
自体の膨潤が生じたり、ひび割れが生ずるため、好まし
くない。The density of sulfonic acid groups on the surface of these dispersed particles is usually 0.001 to 1 per person, preferably 0.01
~0.5 piece/to2. If this density is less than 0.001 particles/person2, the dispersion stability of the dispersed particles becomes insufficient and aggregation tends to occur in the electrolyte aqueous solution, while on the other hand, 1 particle/person2
If it exceeds this range, the hydrophilicity of the dispersed particles becomes too large, causing swelling or cracking of the particles themselves, which is not preferable.
本発明において、上記分散粒子が分散される電解質水溶
液のための電解質としては、例えば塩化ナトリウム、塩
化カリウム、リン酸ナトリウム、リン酸2ナトリウム、
リン酸1ナトリウム、リン酸カリウム、リン酸2カリウ
ム、リン酸1カリウム、クエン酸ナトリウム、ベンゼン
スルホン酸ナトリウム、サリチル酸す、トリウム、炭酸
ナトリウム、炭酸水素ナトリウム、ホウ酸ナトリウム、
塩酸、硫酸、水酸化ナトリウム、塩化アンモニウムなど
を使用することができ、また、その1種のみでなく、2
種以上を用いることもできる。これらの電解質水溶液中
の電解質濃度は0.1〜20重量%が好ましい。In the present invention, examples of the electrolyte for the electrolyte aqueous solution in which the dispersed particles are dispersed include sodium chloride, potassium chloride, sodium phosphate, disodium phosphate,
Monosodium phosphate, potassium phosphate, dipotassium phosphate, monopotassium phosphate, sodium citrate, sodium benzenesulfonate, salicylate, thorium, sodium carbonate, sodium bicarbonate, sodium borate,
Hydrochloric acid, sulfuric acid, sodium hydroxide, ammonium chloride, etc. can be used, and not only one of them, but also two
More than one species can also be used. The electrolyte concentration in these electrolyte aqueous solutions is preferably 0.1 to 20% by weight.
また、これらの電解質水溶液の具体例としては、r l
5OTON−U J (コールタ−社製)、生理食塩
水などを挙げることができる。Further, as specific examples of these electrolyte aqueous solutions, r l
5OTON-UJ (manufactured by Coulter), physiological saline, and the like.
電解質水溶液中に分散される分散粒子の数は、使用する
血球計数器の希釈倍率によって異なるが、通常、第1の
粒子は4 XIO’〜3 XIO’個/mi’、第2の
粒子は4X10’〜12X10’個/rnlの範囲内と
され、また、第1の粒子の数と第2の粒子の数との割合
は1;10〜40、好ましくは1:15〜20とされる
。そして、血球計数器による計測値が、第1の粒子につ
いては2〜3 XIO@個/mi!、第2の粒子につい
ては 4〜5X10s個/rnlの範囲の数値として表
示されるのが好ましい。The number of dispersed particles dispersed in the electrolyte aqueous solution varies depending on the dilution ratio of the hemocytometer used, but usually the number of the first particles is 4XIO' to 3XIO'/mi', and the number of the second particles is 4X10 The number of particles is within the range of 12×10 particles/rnl, and the ratio of the number of first particles to the number of second particles is 1:10 to 40, preferably 1:15 to 20. The measurement value by the hemocytometer was 2 to 3 XIO@particles/mi for the first particle! , the second particle is preferably expressed as a numerical value in the range of 4 to 5×10s particles/rnl.
本発明の標準液は、電解質水溶液を着色し、その吸収ス
ペクトルをシアンメトヘモグロビンと同様のものとする
ことにより、血液中のヘモグロビン濃度の測定に用いる
標準液としても用いることができる。The standard solution of the present invention can also be used as a standard solution for measuring hemoglobin concentration in blood by coloring the electrolyte aqueous solution and making its absorption spectrum similar to that of cyanmethemoglobin.
このような着色のためには、酸性染料および/または直
接染料を2種以上組合せて水性媒体を着色し、シアンメ
トヘモグロビンの光吸収特性と同様に、波長540nm
に最大吸収を有しかつその吸収スペクトルが540nm
付近において平坦であるような吸収特性を有するものと
すればよい。For such coloring, the aqueous medium is colored with a combination of two or more acidic dyes and/or direct dyes, and similar to the light absorption characteristics of cyanmethemoglobin, a wavelength of 540 nm is obtained.
has a maximum absorption at 540 nm and its absorption spectrum is 540 nm.
What is necessary is to have absorption characteristics that are flat in the vicinity.
ここに使用される染料は、酸性染料および/または直接
染料であり、それ以外の染料、例えば塩基性染料や油性
染料は、標準液容器、計測セル、分散粒子、計測セルに
付着した血清蛋白質などをも染色してしまうため、計測
において誤差の原因となる。The dyes used here are acidic dyes and/or direct dyes, and other dyes, such as basic dyes and oil-based dyes, are used to dye the standard solution container, measurement cell, dispersed particles, serum proteins attached to the measurement cell, etc. It also stains the skin, causing errors in measurements.
好適に使用される酸性染料の具体例としては、例えばア
ンラドレッド8、同26、同27、同35、同37、同
49、同52、同131、同134、同138、同14
5、同224、同249、同254、同274、アシッ
ドバイオレット49、同51、食用赤色2号、同3号、
同102号、同104号、同105号、同106号など
を挙げることができる。また、直接染料の具体例として
は、例えばダイレクトレッド9、同3L同224、ダイ
レクトバイオレット51などを挙げることができる。こ
れらのうち、好ましいものはアンラドレッド8、同26
、同27、同35、同37、同52、同145、同22
4、同254およびダイレクトレッド224である。Specific examples of acidic dyes that are preferably used include, for example, Anradred 8, Anradred 26, Anradred 27, Anradred 35, Anradred 37, Anradred 49, Anradred 52, Anradred 131, Anradred 134, Anradred 138, Anradred 14.
5, 224, 249, 254, 274, Acid Violet 49, 51, Food Red No. 2, No. 3,
Examples include No. 102, No. 104, No. 105, and No. 106. Specific examples of direct dyes include Direct Red 9, Direct Red 9, Direct Red 3L, Direct Violet 51, and the like. Among these, preferable ones are Undradred 8 and Undradred 26.
, 27, 35, 37, 52, 145, 22
4, 254 and Direct Red 224.
これらの染料は500〜550 nmに最大吸収を有す
るものであるが、その2種が組合せられて使用されるこ
とにより、例えば540nmをその範囲に含むlQnm
程度以上の波長領域にわたって平坦な吸収特性を得るこ
とができる。この平坦部の最高吸光度と最低吸光度との
差は、通常、0.02以下、好ましくは0.01以下で
ある。These dyes have a maximum absorption in the range of 500 to 550 nm, but when two of them are used in combination, it is possible to obtain
It is possible to obtain flat absorption characteristics over a wavelength range of more than 100%. The difference between the maximum absorbance and the minimum absorbance of this flat portion is usually 0.02 or less, preferably 0.01 or less.
このような特性を得るために好適な染料の組合せの具体
例としては、〔アシッドレッド35/食用赤色2号/食
用赤色106号J1 〔アシッドレッド35/アシツド
レツド254〕、〔アシッドレッド37/ダイレクトレ
ツド224〕、〔アシッドレッド27/アシツドレツド
35/アシツドレツド52〕などを挙げることができ、
特に好ましい染料の組合せは〔アシッドレッド37/ダ
イレクトレツド224〕および〔アシッドレッド27/
アシツドレツド35/アシツドレツド52〕である。Specific examples of dye combinations suitable for obtaining such properties include [Acid Red 35/Food Red No. 2/Food Red No. 106 J1 [Acid Red 35/Acid Red 254], [Acid Red 37/Direct Red]. [Acid Red 224], [Acid Red 27/Acid Red 35/Acid Red 52], etc.
Particularly preferred dye combinations are [Acid Red 37/Direct Red 224] and [Acid Red 27/
Assisted Dred 35/Assisted Dred 52].
これらの染料の使用量は、通常、標準液中においてlp
pmから10重量%、好ましくは2 ppmから5重量
%の範囲内となる量であり、血球計数器で用いる希釈倍
率と標準液としての必要な吸光度により適宜決定される
。The amount of these dyes used is usually 1p in the standard solution.
The amount is within the range of 10% by weight from pm, preferably from 2 ppm to 5% by weight, and is appropriately determined depending on the dilution ratio used in the hemocytometer and the absorbance required as a standard solution.
なお、本発明の標準液には、必要に応じて染色防止剤、
防菌・防黴剤などの添加剤を添加することができる。In addition, the standard solution of the present invention may contain an anti-staining agent, if necessary.
Additives such as antibacterial and antifungal agents can be added.
染色防止剤としては、エチルセロソルブなどのアルコー
ル類;安息香酸す) IJウム、酒石酸ナトリウム、乳
酸す) IJウムなどの有機酸塩類;親水性シリコーン
化合物などを挙げる−ことができる。Examples of the stain inhibitor include alcohols such as ethyl cellosolve; organic acid salts such as benzoic acid, sodium tartrate, and lactic acid; hydrophilic silicone compounds, and the like.
これらは、標準液容器、計測上ノへ分散粒子、計測セル
に付着した血清蛋白質などの染色をより完全に防止し、
安定した吸光度測定を達成するために用いる。These more completely prevent staining of serum proteins adhering to the standard solution container, particles dispersed on the measurement surface, and measurement cells.
Used to achieve stable absorbance measurements.
また、防菌・防黴剤としては、例えばす) IJウムジ
アジド、安息香酸ナトリウム、サリチル酸ナトリウムな
どを挙げることができる。Examples of antibacterial/antifungal agents include IJumdiazide, sodium benzoate, and sodium salicylate.
以下、本発明の実施例について具体的に説明するが、本
発明がこれらによって限定されるものではない。Examples of the present invention will be described in detail below, but the present invention is not limited thereto.
実施例1
粒子Δ
スチレンとメチルメタクリレートとの重量比が98:2
であるスチレン−メチルメタクリレート共重合体よりな
る実質上球形の粒子(平均粒径2.08μs、変動係数
2.5%)10gを100m1の濃硫酸中に加え、かき
まぜながら60℃でスルホン化反応を1時間行い、反応
復水酸化ナトリウムで中和し、十分に水洗して、表面に
スルホン酸基を有する実質上球形の粒子Aを得た。この
粒子Aの平均粒径は2、09gm、変動係数は2.5%
であり、電導度滴定により求めたスルホン酸基の密度は
0.22個/人2であった。Example 1 Particle Δ Weight ratio of styrene to methyl methacrylate is 98:2
10 g of substantially spherical particles (average particle size 2.08 μs, coefficient of variation 2.5%) made of styrene-methyl methacrylate copolymer were added to 100 ml of concentrated sulfuric acid, and the sulfonation reaction was carried out at 60°C with stirring. The reaction was carried out for 1 hour, neutralized with reaction condensate sodium hydroxide, and thoroughly washed with water to obtain substantially spherical particles A having sulfonic acid groups on the surface. The average particle size of this particle A is 2.09 gm, and the coefficient of variation is 2.5%.
The density of sulfonic acid groups determined by conductivity titration was 0.22/person2.
粒子B
スチレンとメチルメタクリレートとの重量比が98:2
であるスチレン−メチルメタクリレート共重合体よりな
る実質上球形の粒子(平均粒径5.16μs、変動係数
1.4%)を用いたほかは、粒子Aと同様にして、表面
にスルホン酸基を存する実質上球形の粒子Bを得た。こ
の粒子Bの平均粒径は5.30μs、変動係数は1.5
%であり、電導度滴定により求めた、スルホン酸基の密
度は0.23個/入2であった。Particle B The weight ratio of styrene and methyl methacrylate is 98:2
Sulfonic acid groups were added to the surface in the same manner as Particle A, except that substantially spherical particles (average particle diameter 5.16 μs, coefficient of variation 1.4%) made of styrene-methyl methacrylate copolymer were used. Substantially spherical particles B were obtained. The average particle diameter of this particle B is 5.30 μs, and the coefficient of variation is 1.5
%, and the density of sulfonic acid groups determined by conductivity titration was 0.23 pieces/2.
標準液の調製
約0.9重量%の塩化カリウムを含有する電解質水溶液
中に、上記粒子へを5.5XIQ’個/rn!、、上記
粒子BをI XIO’個/−の割合(粒子A:泣子B=
11g)で添加して分散させて標準液1を得た。Preparation of standard solution In an electrolyte aqueous solution containing about 0.9% by weight of potassium chloride, 5.5XIQ'/rn! of the above particles were added. ,, the ratio of I
Standard solution 1 was obtained by adding and dispersing the solution (11 g).
測定
以上の標準液1について、当該標準液1の調製当日およ
びこれより室温で3力月間静置した後において、血球計
数器rPc 601J (■エルマ社製)および同r
PC604J (■エマル社製)を用いて計測を行っ
たところ、表示された血小板数、赤血球数およびヘマト
クリット (Ht>値(W+ntrobe法による)は
第1表に示すとおりであった。Regarding the standard solution 1 that is above the measurement level, on the day of preparation of the standard solution 1 and after it has been allowed to stand at room temperature for 3 months, use a hemocytometer rPc 601J (manufactured by Elma) and the same rPc 601J (manufactured by Elma)
Measurement was performed using PC604J (manufactured by Emaru Co., Ltd.), and the displayed platelet count, red blood cell count, and hematocrit (Ht> value (by W+ntrobe method) were as shown in Table 1.
第 1 表
第1表の結果から、この標準液1は、3力月後において
も、調製当初と同等の特性を有し、分散安定性が優れて
いることが明らかである。また、この標準液1は、軽い
振り混ぜによって十分に粒子が分散し、各測定時の5回
の測定においても、計測結果にばらつきは認められなか
った。Table 1 From the results in Table 1, it is clear that even after 3 months, this standard solution 1 had the same properties as at the time of preparation and had excellent dispersion stability. Further, in this standard solution 1, the particles were sufficiently dispersed by gentle shaking, and no variation was observed in the measurement results even in the five measurements at each measurement.
比較例1
粒子へと同様にして得た、ヒトの正常赤血球の平均粒径
と近似する7、0卿の平均粒径を有する実質上球形の粒
子C(変動係数3.0%、スルホン酸基の密度0.20
個/人2)を用い、粒子Cを8 XIO’個/d、実施
例1で用いた粒子Aを4.4X10’個/dの割合(粒
子A1粒子C=1:18)で分散させて得られた比較用
標準液1について、血球計数器rPc 604Jを用い
て測定を行ったところ、表示された赤血球数は4.05
X10’個/mlであって特に問題はないが、表示され
たヘマトクリット値は48.8%であり、赤血球数4
Xl09個/艶から計算されるヘマトクリット値約34
%から大きく外れるものであった。Comparative Example 1 Substantially spherical particles C (coefficient of variation 3.0%, sulfonic acid group Density of 0.20
The particles C were dispersed at a ratio of 8 XIO' particles/d and the particles A used in Example 1 were dispersed at a ratio of 4.4 When the obtained comparison standard solution 1 was measured using a hemocytometer rPc 604J, the number of red blood cells displayed was 4.05.
Although the number of red blood cells/ml is not particularly problematic, the displayed hematocrit value is 48.8%, and the number of red blood cells is 4.
Hematocrit value approximately 34 calculated from Xl09 pieces/gloss
%.
比較例2
粒子D
スチレンとn−ブチルアクリレートとの重量比が70:
30であるスチレン−n−ブチルアクリレート共重合体
よりなる実質上球形の粒子(平均粒径2、88ua、変
動係数1.5%)10gを100m!、の2Nの水酸化
す)IJウムに加え、かきまぜながら80℃で8時間加
水分解を行い、十分に水洗して、表面にカルボキシル基
を有する実質上球形の粒子りを得た。この粒子りの平均
粒径は2.85gm、変動係数は1.9%であり、電導
度滴定により求めたカルボキシル基の密度は0.35個
/人2であった。Comparative Example 2 Particle D The weight ratio of styrene and n-butyl acrylate is 70:
30, substantially spherical particles (average particle size 2, 88 ua, coefficient of variation 1.5%) of 100 m! The mixture was added to 2N IJ hydroxide and hydrolyzed at 80° C. for 8 hours with stirring, and thoroughly washed with water to obtain substantially spherical particles having carboxyl groups on the surface. The average particle size of the particles was 2.85 gm, the coefficient of variation was 1.9%, and the density of carboxyl groups determined by conductivity titration was 0.35 pieces/person2.
粒子E
スチレンとn−ブチルアクリレートとの重量比が70二
30であるスチレン−n−ブチルアクリレート共重合体
よりなる実質上球形の粒子(平均粒径5.25μs、変
動係数2.3%)を用いたほかは、粒子りと同様にして
、表面にカルボキシル基を有する実質上球形の粒子Eを
得た。この粒子Eの平均粒径は5.28JLII+、変
動係数は2.3%であり、電導度滴定により求めたカル
ボキシル基の密度は0.56個/人2であった。Particle E Substantially spherical particles (average particle diameter 5.25 μs, coefficient of variation 2.3%) made of styrene-n-butyl acrylate copolymer with a weight ratio of styrene and n-butyl acrylate of 70 to 30. Substantially spherical particles E having carboxyl groups on the surface were obtained in the same manner as in the particle preparation except that particles E were used. The average particle diameter of the particles E was 5.28JLII+, the coefficient of variation was 2.3%, and the density of carboxyl groups determined by conductometric titration was 0.56/person2.
標準液の調製
実施例1と同様の電解質水溶液中に、上記粒子りを5.
5X10’個/m!!、上記粒子Eを1×105個/−
の割合〈粒子D:粒子E=1:1B)で添加して分散さ
せて比較用標準液2を得た。Preparation of standard solution The above particles were added to the same electrolyte aqueous solution as in Example 1 in 5.
5X10' pieces/m! ! , the above particles E are 1 x 105 pieces/-
A comparative standard solution 2 was obtained by adding and dispersing the particles at a ratio of (Particle D: Particle E = 1:1 B).
この比較用標準液2について、実施例1と同様にして、
調製当日および室温で1力月間静置した後に測定を行っ
たところ、表示された血小板数および赤血球数は第2表
に示すとおりであった。Regarding this comparative standard solution 2, in the same manner as in Example 1,
Measurements were performed on the day of preparation and after one month of standing at room temperature, and the displayed platelet counts and red blood cell counts were as shown in Table 2.
第2表
第2表の結果から、この比較用標準液2は、1力月後に
おいては、表示された計測値が低下し、保存安定性が低
いことが明らかである。From the results shown in Table 2, it is clear that the displayed measurement value of Comparative Standard Solution 2 decreased after one month, and the storage stability was low.
実施例2
実施例1で得た標準液1に、アシッドレッド35とアシ
ッドレッド254とを1;1の割合で濃度が3ppmと
なるように添加して溶解した。Example 2 Acid Red 35 and Acid Red 254 were added and dissolved in the standard solution 1 obtained in Example 1 at a ratio of 1:1 so that the concentration was 3 ppm.
この着色標準液1の最大吸収は波長515〜545nm
であり、この範囲の吸光度は0.2±0.003 と平
坦であり、しかもこの着色標準液1は、プラスチツク容
器、ガラスまたは石英セルを染色することがなく、しか
もヒト血清アルブミンが吸着したガラスをも染色しない
ものであった。The maximum absorption of this colored standard solution 1 is at a wavelength of 515 to 545 nm.
The absorbance in this range is flat at 0.2 ± 0.003, and this colored standard solution 1 does not stain plastic containers, glass or quartz cells, and it does not stain glass to which human serum albumin has been adsorbed. It also did not stain.
本発明の標準液は、分散された粒子がいずれも表面にス
ルホン酸基を有するものであるため、界面活性剤などを
添加することなしに粒子が高い分散安定性を有し、保存
安定性が大きく、また各々特定の平均粒径を有する2種
の実質上球形の粒子が特定の割合で含有されるため、血
球計数器による赤血球や血小板の計測およびヘマトクリ
ット値の計測のいずれについても十分に信頼性の高い結
果が表示されることとなる。In the standard solution of the present invention, all of the dispersed particles have sulfonic acid groups on their surfaces, so the particles have high dispersion stability and storage stability without adding surfactants. Because it is large and contains a specific proportion of two types of substantially spherical particles, each with a specific average particle size, it is fully reliable for both red blood cell and platelet measurements and hematocrit measurements using a hemocytometer. Results with high quality will be displayed.
Claims (1)
を有し平均粒径が1.9〜3μmで変動係数が5%以下
である、実質上球形の第1の粒子と、この第1の粒子の
数の10〜40倍の割合となる数の、表面にスルホン酸
基および/またはスルホン酸塩基を有し平均粒径が4.
5〜5.5μmで変動係数が5%以下である、実質上球
形の第2の粒子とが、電解質水溶液中に分散されている
ことを特徴とする血球計数器校正用標準液。1) Substantially spherical first particles having a sulfonic acid group and/or a sulfonic acid group on the surface, an average particle size of 1.9 to 3 μm, and a coefficient of variation of 5% or less, and this first particle The particles have a number of sulfonic acid groups and/or sulfonic acid groups on the surface in a ratio of 10 to 40 times the number of particles with an average particle size of 4.
A standard solution for calibrating a hemocytometer, characterized in that substantially spherical second particles having a diameter of 5 to 5.5 μm and a coefficient of variation of 5% or less are dispersed in an aqueous electrolyte solution.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP13015088A JPH01301166A (en) | 1988-05-30 | 1988-05-30 | Standard liquid for calibrating blood cell counter |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP13015088A JPH01301166A (en) | 1988-05-30 | 1988-05-30 | Standard liquid for calibrating blood cell counter |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH01301166A true JPH01301166A (en) | 1989-12-05 |
Family
ID=15027176
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP13015088A Pending JPH01301166A (en) | 1988-05-30 | 1988-05-30 | Standard liquid for calibrating blood cell counter |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH01301166A (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04278460A (en) * | 1991-03-06 | 1992-10-05 | Shima Kenkyusho:Kk | Method for controlling examination result of urine sediment, control marker particle and preparation thereof |
US5888823A (en) * | 1995-11-17 | 1999-03-30 | Toa Medical Electronics Co., Ltd. | Standard fluid for flow cytometer |
EP0965841A1 (en) * | 1998-04-06 | 1999-12-22 | AVL Medical Instruments AG | Control or calibration standard for instruments for the optical determination of hemoglobin concentration in blood samples |
US6174728B1 (en) | 1998-04-03 | 2001-01-16 | Avl Medical Instruments Ag | Control or calibration standard for use with instruments for optical measurement of hemoglobin concentration in blood samples |
JP2008534957A (en) * | 2005-04-04 | 2008-08-28 | バイオ−ラッド ラボラトリーズ,インコーポレイティド | Manufacture of platelet analogs |
CN103884630A (en) * | 2014-03-13 | 2014-06-25 | 河北联合大学 | Determination method for dispersity of dust in air of working field |
JP2016145834A (en) * | 2016-03-16 | 2016-08-12 | ソニー株式会社 | Microparticle separator and calibration particle |
-
1988
- 1988-05-30 JP JP13015088A patent/JPH01301166A/en active Pending
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04278460A (en) * | 1991-03-06 | 1992-10-05 | Shima Kenkyusho:Kk | Method for controlling examination result of urine sediment, control marker particle and preparation thereof |
US5888823A (en) * | 1995-11-17 | 1999-03-30 | Toa Medical Electronics Co., Ltd. | Standard fluid for flow cytometer |
US6174728B1 (en) | 1998-04-03 | 2001-01-16 | Avl Medical Instruments Ag | Control or calibration standard for use with instruments for optical measurement of hemoglobin concentration in blood samples |
EP0965841A1 (en) * | 1998-04-06 | 1999-12-22 | AVL Medical Instruments AG | Control or calibration standard for instruments for the optical determination of hemoglobin concentration in blood samples |
JP2008534957A (en) * | 2005-04-04 | 2008-08-28 | バイオ−ラッド ラボラトリーズ,インコーポレイティド | Manufacture of platelet analogs |
CN103884630A (en) * | 2014-03-13 | 2014-06-25 | 河北联合大学 | Determination method for dispersity of dust in air of working field |
JP2016145834A (en) * | 2016-03-16 | 2016-08-12 | ソニー株式会社 | Microparticle separator and calibration particle |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2273384T3 (en) | USE OF SYNTHETIC POLYMERIC PARTICLES AS PRATONS AND CALIBRATORS IN FLOW CYTOMETRY. | |
CN106198527B (en) | A kind of ascorbic acid interference multi-term urine analysis test paper and preparation method thereof | |
US20070142595A1 (en) | Oval-spherical organic polymer particle and process for producing the same | |
JPH07503792A (en) | A method for accurately enumerating heterogeneous cell populations and grading their sensitivity under cell lysis treatment conditions | |
JPH01301166A (en) | Standard liquid for calibrating blood cell counter | |
CN107894509B (en) | A method of improving latex immunoturbidimetry antigen excess and the range of linearity | |
US20070054123A1 (en) | Oval-spherical organic polymer particles and method of production | |
JPH11326331A (en) | Reference solution for quality control and calibration for device for optically measuring hemoglobin concentration in blood sample | |
CA1086197A (en) | Single sample method for determination of lipoprotein concentrations in blood | |
CA1250805A (en) | Latex for immunoserological tests and a method for the production of the same | |
CN107328766B (en) | Method for determining content of carbomer in carbomer-containing gel | |
JPS6244609B2 (en) | ||
KR101440938B1 (en) | Reagent for assaying antiphospholipid antibody and reagent for assaying anti-treponema pallidum antibody | |
Márquez-Islas et al. | Optical device and methodology for optical sensing of hemolysis in hypotonic media | |
US20210080455A1 (en) | Organic Colored Microparticles, Diagnostic Reagent Kit, and In Vitro Diagnosis Method | |
US20140295576A1 (en) | Insoluble carrier for use in anti-phospholipid antibody measurement reagent, anti-phospholipid antibody measurement reagent, and method for measuring anti-phospholipid antibody | |
Bradbury | A simplified method for the estimation of sodium | |
Diehl et al. | Studies on fluorescein—III: The acid strengths of fluorescein as shown by potentiometric titration | |
WO1992018863A1 (en) | Composition for measuring ionic strength or specific gravity of liquid specimen and test piece prepared from said composition | |
JPH0731101B2 (en) | Particle counter Calibration particles | |
JP3717582B2 (en) | Fine particles | |
JP6482916B2 (en) | Colored particle dispersion and colored particle storage method | |
CN106674401A (en) | Preparation method of polystyrene latex with carboxyl on surface for immunodetection technique | |
JPH01234401A (en) | Production of polymer fine granule | |
JPH0231162A (en) | Method for counting acidocyte |